Excision repair cross-complementing group 1

Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer

H. Yang, Li, G., and Li, W. F., Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer, vol. 14, pp. 700-705, 2015.

We conducted a hospital-based case-control study to evaluate the association between polymorphisms in excision repair cross-complementing group 1-xeroderma pigmentosum group F (ERCC1-XPF) variants and the risk of colorectal cancer in a Chinese population. Genotyping of the ERCC1 rs2298881 and rs11615 and XPF rs2276466 polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism. Colorectal cancer cases were more likely to be smokers, consume alcohol, have higher energy intake, and have a family history of cancer.

ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

H. Zhang, Li, J., Zhang, Y., Sun, M., Zhao, P., Zhang, G., Jin, C., Sun, L., He, M., Wang, B., and Zhang, X., ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy, vol. 13, pp. 10215-10222, 2014.

We conducted a prospective study to analyze the expression of the excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) genes in 297 Chinese patients with advanced non-small cell lung cancer (NSCLC). The goal of this study was to evaluate these genes as potential biomarkers for prediction of tumor response and clinical outcome. Patients with unresectable, locally advanced or metastatic NSCLC were enrolled between September 2007 and September 2009, and they were followed up until September 2012.

Subscribe to Excision repair cross-complementing group 1